This inventor holds 1 USPTO granted patent and 7 published patent applications and 1 EPO patent. Top assignee: Amunix Pharmaceuticals, Inc. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: André Frenzel: Innovator in Biopharmaceuticals
Introduction
André Frenzel is a notable inventor based in Braunschweig, Germany. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapies targeting specific receptors.
Latest Patents
Frenzel holds a patent titled "Compositions targeting epidermal growth factor receptor and methods for making and using the same." This patent describes antibody binding domains for the cluster of differentiation 3 T cell receptor (CD3) and the epidermal growth factor receptor (EGFR). It also includes cleavable linker sequences and protease-activatable bispecific fusion proteins, such as protease-activatable T cell engagers, along with their uses and methods of treatment. He has 1 patent to his name.
Career Highlights
Throughout his career, Frenzel has worked with several prominent companies in the biopharmaceutical sector. Notably, he has been associated with Amunix Pharmaceuticals, Inc. and Arntz Beteiligungs GmbH & Co. KG. His work in these organizations has contributed to advancements in therapeutic strategies and drug development.
Collaborations
Frenzel has collaborated with various professionals in his field, including Viktoriya Dubrovskaya and Eric Johansen. These partnerships have fostered innovation and the exchange of ideas, further enhancing the impact of his work.
Conclusion
André Frenzel is a distinguished inventor whose work in biopharmaceuticals has led to significant advancements in targeted therapies. His contributions continue to influence the field and pave the way for future innovations.